Voluntary Scheme for Branded Medicines, Pricing, Access and Growth (VPAG)

The new VPAG scheme is due to come in effect in January 2024 lasting for 5 years. The scheme, which has been agreed between the UK Government, NHS England and the Association of the British Pharmaceutical Industry (ABPI), aims to improve access to innovative treatments for NHS patients whilst supporting NHS financial sustainability and improving the competitiveness of the UK Life Sciences industry.

Our Market Access Team has digested the information and produced some key implications for pharmaceutical companies. Please complete the form to the right to download the resource.